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C A N C E R
Hormone autocrination by vascularized  
hydrogel delivery of ovary spheroids to rescue  
ovarian dysfunctions
Hyo-Jin Yoon1†, Yong Jae Lee2,3†, Sewoom Baek1, Young Shin Chung2,3, Dae-Hyun Kim1,  
Jae Hoon Lee3,4, Yong Cheol Shin1,  Young Min Shin1, Chungsoon Ryu2, Hye-Seon Kim1,  
So Hyun Ahn2,3, Heeyon Kim2,3, Young Bin Won2,3, Inha Lee2,3, Myung Jae Jeon5, Si Hyun Cho2,4, 
Byung Seok Lee2,3, Hak-Joon Sung1*, Young Sik Choi2,3*
The regeneration potential of implantable organ model hydrogels is applied to treat a loss of ovarian endocrine 
function in women experiencing menopause and/or cancer therapy. A rat ovariectomy model is used to harvest 
autologous ovary cells while subsequently producing a layer-by-layer form of follicle spheroids. Implantation of 
a microchannel network hydrogel with cell spheroids [vascularized hydrogel with ovarian spheroids (VHOS)] 
into an ischemic hindlimb of ovariectomized rats significantly aids the recovery of endocrine function with hor-
mone release, leading to full endometrium regeneration. The VHOS implantation effectively suppresses the 
side effects observed with synthetic hormone treatment (i.e., tissue overgrowth, hyperplasia, cancer progres-
sion, deep vein thrombosis) to the normal levels, while effectively preventing the representative aftereffects of 
menopause (i.e., gaining fatty weight, inducing osteoporosis). These results highlight the unprecedented ther-
apeutic potential of an implantable VHOS against menopause and suggest that it may be used as an alternative 
approach to standard hormone therapy.
INTRODUCTION
The human organ-mimetic system has received immense attention 
because of its capability to mimic living organ function and patho-
physiology (1). Implantation of this system can restore organ func-
tion and structure with tissue regeneration (2, 3). To date, these dual 
utilities have never been clearly demonstrated in a model of critical 
aging disease. Menopause limits normal physiological activities due to 
a loss of ovarian function (4). For example, primary ovarian insuffi-
ciency hinders fertility functions in menopausal women (<40 years old) 
because of a decrease in the number of follicles at a premature stage 
(5, 6). These menopausal situations are often accompanied by vaso-
motor symptoms, urogenital atrophy, osteoporosis and fracture, 
cardiovascular disease, and an increased all-cause mortality. Systemic 
hormone therapy is the standard treatment for menopause (7, 8), 
but the Women’s Health Initiative report shows increased risks as-
sociated with the standard hormone therapy, including breast cancer, 
venous thromboembolism, stroke, and coronary artery disease (9). 
These reported risks resulted in a 50% drop in the use of standard 
hormone therapy (4). This indicates that there is an urgent need for 
an alternative approach to replace hormone therapy (6).
A follicle has a spheroid structure with multilayers of oocyte and 
granulosa (G)/theca (T) cells that operate major ovary functions like 
reproductive hormone production (e.g., estradiol and progesterone) 
and luteinizing hormone (LH)–mediated activity. The follicle func-
tions are regulated by the feedback mechanism of the hypothalamic- 
pituitary-ovarian (HPO) axis. The systemic hormone therapy skips 
this feedback mechanism and, therefore, has limitations in controlling 
the therapeutic hormone levels with the aforementioned side effects 
(10). Artificial follicles engineered with cultures of autologous cells 
in an organ model system are a promising solution to address the 
side effects associated with the standard hormone therapy (11). Con-
tinuous progress has been made in this area of research, and recent 
efforts include applying an engineered tissue scaffold to ovariecto-
mized mice (12), producing live births in pseudopregnant mice (13), 
restoring hormone cyclicity after implantation (14), growing isolated 
follicles, and inducing in vivo production of female reproductive 
hormones to mimic the human menstrual cycle (15). Despite these 
promising results, sequential processes, such as artificial follicle 
production by applying a microchannel hydrogel with culture of 
autologous ovarian spheroids [vascularized hydrogel with ovarian 
spheroids (VHOS)], in vivo implantation and hormone release, and 
ovarian tissue regeneration together with functional restoration, have 
never been clearly established with regard to its clinical translation.
Hence, several breakthrough factors were applied in this study to 
establish the aforementioned process. First, the recovery of endo-
crine function was aided significantly by forced aggregation of follicle 
cells. The underlying cell-cell interaction was promoted by match-
ing the number and cell type with those of native follicles, as shown 
in a previous study (16). The cell-matrix interaction was also facili-
tated by coating the outer layer of the spheroid core (G cells) with 
basal lamina–like extracellular matrix (ECM). Second, the VHOS-
based culture enabled in vitro structural maturation and in vivo 
functional maintenance of artificial follicles for 7 weeks after VHOS 
implantation. This method is also relatively simple and suitable 
to apply to a large-scale production of artificial follicles for use 
in future clinical applications (17). Third, cooperation of the 
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microvasculature-mimetic microchannel network of the VHOS, with 
the hindlimb ischemia model, induced the formation of perfusion 
connections with host vessels, thereby serving as an on-site depot to 
release hormones in a sustained and controlled fashion. These find-
ings are supported by our previous study (18), in that ischemia trig-
gered the growth of host vessels into a microchannel hydrogel 
implant and further perfused blood into microchannels. By using 
this technique, hormone can be released from the VHOS into the 
systemic circulation and facilitate the operation of endocrine func-
tions, which indicate an unprecedented role for the VHOS in re-
placing the functions of the ovary. These points were demonstrated 
in the following study in both in vitro and in vivo experiments.
RESULTS
Ovary cells and artificial follicles
Artificial follicle spheroids were produced by first harvesting ovarian 
tissues from female rats with subsequent isolation of G and T cells 
from these tissues by Percoll gradient separation (Fig. 1). Multilayer 
cell spheroids were then produced by forming G cell spheroids in 
AggreWell (STEMCELL Technologies, Vancouver, Canada). This 
procedure was followed by Matrigel (M) coating and/or T cell load-
ing onto the spheroids to mimic the native ovarian follicle (Fig. 1A). 
Next, spheroids of G and T cells (GT) and G cells, M coating, and 
T cells (GMT) were tested to determine the basal lamina role of M 
in follicle maturation and endocrine function. The phenotypic 
purity of each G or T cell type was promoted incrementally through 
a series of subculturing, as clearly evidenced by the full protein ex-
pression (>95%) of CYP19 (aromatase) and CYP17A (17, 20 lyase) 
in G and T cells, respectively. These results are shown in the quan-
titative image analyses of the fluorescence images (Fig. 1B) and flow 
cytometry results (Fig. 1C). As opposed to the indistinct layer for-
mation of the GT group, the GMT group maintained a stable core 
of G cells with a robust shell layer of T cells, when observed under 
confocal imaging of the three-dimensional (3D) spheroid structures 
(Fig. 1D). Western blot analysis showed that this combination in 
2-week culture at AggreWell without gelatin coating and perfusion 
resulted in promotion of cell proliferation [e.g., proliferating cell 
nuclear antigen (PCNA) and cyclin D1] and hormone secretion 
[e.g., estrogen (FSH-R) and progesterone (LH-R)] compared with 
the GT spheroid (Fig. 1E). The results confirmed that the coating of 
the basal lamina mimetic significantly contributed to the successful 
production of hormone, cell growth, and superior function of arti-
ficial follicles as a form of multilayered GMT spheroid.
Culture in a 3D channel network hydrogel
Blood circulation is the major route used to deliver systemic hormone 
therapy; therefore, highly interconnected, dense channel networks 
were generated to overcome the 200-m diffusion limit of a 3D 
hydrogel [vascularized hydrogel (VH)] (2) with the culture of the 
artificial follicles. This procedure is displayed schematically (Fig. 2A). 
A chamber was cast by pouring polydimethylsiloxane (PDMS) into 
a 3D printed mold to act as a container for the VH in a perfusion 
setting, with connection to a pump. Then, using the principle 
of a cotton candy machine, threads of dense, thermo-responsive 
poly(N-isopropylacrylamide) (PNIPAM) fibers were produced by 
spinning and then placed into the PDMS chamber. Next, to create a 
hydrogel material, a gelatin solution was mixed with G(M) T spheroids, 
poured to cover the fiber threads in the chamber, and subsequently 
subjected to enzyme-crosslinked gelation. Last, the PNIPAM fibers 
were dissolved at 37°C to form perfusable channel networks in the 
gelatin gel. This VH served as a tunable in vitro and in vivo culture 
platform for the cell spheroids by continuously perfusing culture 
medium into channel networks. A dynamic culture condition, estab-
lished with a medium flow rate of 20 l/min using a peristaltic pump, 
was compared with a static culture condition under gravity-based, pas-
sive medium flow. Perfusion across spheroids embedded in the VH 
was enabled by controlling the density of PNIPAM fibers at 11.45 ± 
3.13 g mm−3 when placed in the PDMS mold, as optimized through 
our previous efforts (2, 18). A dynamic blood flow–like pumping 
overcame the diffusion limit and enabled a 30-day long culture.
Cell viability and structural stability in spheroids were well 
maintained in a VH under dynamic culture for 30 days as shown by 
the dominant live cell population, clear channel perfusion, and 3D 
layer-by-layer structure throughout the hydrogel (Fig. 2B). The 
30-day period of perfusion culture was set to match with an average 
menstrual cycle of women (19). The resultant overall data trends 
(Fig. 2C) indicate that the GMT dynamic group maintained the 
highest levels of structural stability (circularity) and expansion of 
spheroids (spheroid diameter), cell viability (live/dead) and prolif-
eration (population change), and hormone secretion (17-estradiol 
and progesterone) during the 30-day culture period, although the 
patterns looked divergent among the test groups. In particular, com-
pared to the other test groups, the superiority of the GMT dynamic 
group with respect to the assay results became significantly apparent 
from days 25 to 30 with the exception of circularity. When the 
stability of the spheroid was disturbed, their structure changes from 
nearly complete circle to an irregular structure, thereby decreasing 
the circularity (complete circle: 1 → 0) (20). Hence, no significant 
differences in the circularity of test groups indicate that the spher-
oids maintained their structural stability during the 30-day culture 
regardless of the culture conditions.
Because the GMT spheroids are inherently larger than GT spher-
oids due to the M layer, the diameter changes among the test groups 
over the course of the 30-day culture were presented (Fig. 2C). 
Moreover, the effect of the initial diameter factor on the analysis of 
cell population was excluded by normalizing the cell population 
values to that of day 1  in each group. In this way, incremental 
changes of cell population in each group were presented by setting 
the day 1 value as a baseline (=1). A total of 1200 spheroids were 
loaded to each VH, resulting in producing about 1.25 pg/GMT 
spheroid of each hormone type at day 30 after perfusion culture. 
The static condition represents a natural ischemic condition, whereas 
the dynamic condition mimics the rescue of hypoxia by oxygen 
supply through perfusion. Hence, the incremental diameter and cell 
population of GMT in the dynamic culture for 30 days with stable 
maintenance of circularity, viability, and hormone secretion indicate 
significant attenuation of negative effects from the ischemic condi-
tion by channel perfusion. Therefore, the GMT group, under dynamic 
culture conditions (VHOS), was used in our follow-up experiments.
Implantation into ovariectomized rats
As seen in our previous studies (2, 21), ischemia induces angiogenesis. 
Consequently, the ischemic hindlimb model of ovariectomized rats 
was used to implant the VH with autologous cell spheroids (VHOS; 
Fig. 3). This in vivo model has unique advantages to induce host 
vessel growth into the VHOS and allow for subsequent perfusion 
connections with channel networks so that GMT spheroids can 
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Fig. 1. Ovary cells and artificial follicle spheroids from rats. (A) (Left) The schematic structure of the native ovarian follicle was mimicked by (right) two forms of artificial 
spheroids in which granulosa (G) cells were encapsulated by a theca (T) cell layer (T layer) without (top, GT) or with (bottom, GMT) Matrigel (M) as a basal lamina (BL) mimetic. 
G and T cells were isolated from ovarian tissues of female rats (3 weeks old) by Percoll gradient separation. Multilayer cell spheroids were produced by first forming G cell 
spheroids in AggreWell, followed by Matrigel (M) coating and/or T cell loading onto the spheroids. (B) Before spheroid formation, the phenotypic purity was enhanced 
by a series of subculturing and then determined by examining the protein expression of CYP19 (aromatase, G cell marker) and CYP17A (17, 20 lyase, T cell marker), respectively. 
The phase contrast and immunofluorescence images were obtained and quantitatively analyzed using ImageJ (AU, arbitrary unit) as an indication of successful purification 
of each cell type. Scale bar, 200 m. (C) The results were confirmed by flow cytometry with quantitative analysis after staining of G and T cells with anti-CYP19–FITC (G cell) 
and anti-CYP17A1–PE (T cells) antibodies, respectively. (D) 3D structures of GMT and GT spheroids were visualized by confocal imaging after labeling G (red) and T (green) 
cells with CellTracker(s). Scale bar, 100 m. (E) The numbers of G and T cells in GMT spheroids were the same as those of GT spheroids. Superior spheroid functions of GMT 
over GT were determined by examining the protein expression of cell proliferation markers (PCNA and cyclin D1) and the secretion of estrogen (FSH-R) and progesterone 
(LH-R) by Western blot with quantitative analysis. Both types of spheroids were cultured at AggreWell for 2 weeks without gelatin coating and perfusion. Data are 
presented as means ± SEM. **P < 0.01, ***P < 0.001 between lined groups.
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Fig. 2. VHOS for spheroid culture in a 3D channel network hydrogel. (A) An implantable VHOS was produced by forming perfusable 3D channel networks inside for 
spheroid culture through the step-by-step procedures as shown in the scheme. (Left) (i) A PDMS chamber was casted by pouring into a 3D printed mold. (ii) Threads of 
thermo-responsive PNIPAM fibers were produced by spinning and placed into the PDMS chamber. (iii) Gelatin solution was mixed with G(M)T spheroids and poured to 
cover the fiber threads in the chamber, followed by enzyme-crosslinked gelation. (iv) The PNIPAM fibers were dissolved out at 37°C to form a perfusable channel network 
in the gelatin gel. (Right) Cell spheroids were cultured by perfusing culture medium into channel networks continuously at a flow rate of 20 l/min using a peristaltic 
pump (dynamic) or through gravity-based medium flow (static). A 30-day culture was conducted to mimic a 30-day menstrual cycle. (B) Cell viability in spheroids was 
maintained in a microchannel hydrogel for 30-day perfusion culture as shown by confocal images (green, live cell; red, dead cell; blue, nucleus; purple, channel network) 
after live/dead staining together with perfusion staining of the channel network in the hydrogel (left). 3D structures of GMT spheroid were visualized by confocal imaging 
after labeling G (red) and T (green) cells with CellTracker(s) (right). Scale bar, 100 m. (C) The 30-day culture’s effects on GMT and GT spheroids in dynamic versus static 
condition were determined by examining (left) structural stability and expansion of spheroids, (middle) cell viability and proliferation, and (right) hormone secretion 
through medium collection every other day. Data are expressed as means ± SEM. *P < 0.05, GT static versus GMT static; †P < 0.05, GT dynamic versus GMT dynamic; 
#P < 0.05, GMT static versus GMT dynamic.
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Fig. 3. Rats underwent both ovariectomy and hindlimb surgery at day 7, and hydrogel implantation at day 14 or hormone injection at day 28 (every 4- to 5-day 
repetition), followed by hormone level measurement every seventh day until euthanization (day 63). (A) Rats underwent either sham operation (group 1: Ovary-intact, 
n = 3) or ovariectomy. Ovariectomized rats were injected with E without (group 2: OVX + E, n = 5) or with P (group 3: OVX + E + P, n = 6). (B) Ischemia-mediated perfusion 
connection between the microchannels and host vessels enables GMT spheroids to release hormones into the blood circulation (group 4: OVX + VHOS, n = 5). Con-
sequently, the endocrine feedback mechanism is activated to treat ovariectomy by VHOS implantation. The last group is OVX with no treatment (group 5: OVX, n = 5). 
(C) The blood perfusion ratio was recovered at day 14 after VHOS implantation, as determined by laser Doppler perfusion imaging (each group, n = 3). (D) Confocal imaging 
(scale bar, 50 m) and (E) perfusion staining of microchannels showed maintenance of GMT viability for 28 days. (F) The endocrine function recovery was determined by 
the circulating plasma levels of hormones. Data are means ± SEM. *P < 0.05 versus group 1; †P < 0.05 versus group 5.
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release hormones from the implant into the host blood circulation. 
The average diameter of microchannels was 16.37 ± 7.76 m as 
determined in our previous study (2). The channels were left open 
without any coating for the in vitro and in vivo studies. The perfu-
sion connection of microchannels with host vessels was induced by 
the unique function of the gelatin hydrogel because the gel cross-
linking by mTG led to matrix deposition of nitric oxide sources, 
thereby promoting growth and invasion of host vessels as reported 
in our previous study (22).
To establish this model (Fig. 3A), female rats (10 weeks old) un-
derwent both ovariectomy and hindlimb ischemia at day 1. Next, 
the rats received either VH implantation with GMT spheroids into 
the hindlimb ischemia site at day 7 or hormone injection at day 21 
with repetition every 4 to 5 days. The 14-day gap from the VHOS 
implantation to the hormone injection was designed to allow for 
perfusion connection of the channel network with host vessels as 
shown in our previous study (2). In this way, the comparison of 
VHOS implantation with the hormone injection group could be 
initiated after the perfusion connection enabled circulation of se-
creted hormones from GMT spheroids. Hormone levels were as-
sessed in blood samples that were drawn every 7 days, until the rats 
were euthanized at day 56. The five test groups (n = 3 to 6 rats) 
included sham operation (group 1: Ovary-intact), ovariectomy with 
estrogen administration alone (group 2: OVX + E), ovariectomy with 
estrogen and progesterone administration (group 3: OVX + E + P), 
ovariectomy with VHOS implantation (group 4: OVX + VHOS), and 
ovariectomy without any treatment (group 5: OVX). Plasma hor-
mones can activate the endocrine feedback mechanism of the HPO 
axis and thereby treat hormone disorders resulting from ovariectomy 
(Fig. 3B). The secretion of gonadotropin-releasing hormone (GnRH) 
from the hypothalamus induces estrogen and testosterone release 
by triggering production of LH and follicle-stimulating hormone 
(FSH) from the pituitary gland. In turn, these sex steroid hormones 
exert feedback actions on the endocrine system, which was the mech-
anism we targeted to regenerate the ovary using VHOS implantation.
Quantitative analysis by Doppler perfusion imaging revealed that 
the blood perfusion ratio throughout the ischemic duct was recov-
ered to ~80% of the normal control at day 14 after limb surgery with 
VHOS implantation (Fig. 3C). Because it takes 2 weeks to complete 
perfusion connections of the microchannel network with in-growing 
host vessels as shown previously (2), the VHOS was implanted at 
2 weeks (i.e., day 7 after ovariectomy with 60% perfusion recovery) 
before injection of synthetic hormone groups so that the 2-week 
period of perfusion connection and further perfusion recovery up 
to 80% enabled fair comparisons of the OVX + VHOS group with 
the other test groups. This result justifies starting the hormone level 
test and injecting the hormone cocktail at day 21 after limb surgery 
(i.e., at day 14 after VHOS implantation). Insufficient perfusion con-
nection between the microchannels in the VHOS and host vessels 
resulted in the inability to rescue endocrine dysfunctions (fig. S1A). 
This result is supported by the findings of significantly lower levels 
of 17-estradiol in the serum of the OVX + VHOS group compared to 
the Ovary-intact group until 13 days after VHOS implantation in con-
trast to the levels of progesterone (fig. S1B). These results confirmed 
the need to implant the VHOS for a 2-week period before compar-
ing the effects of the VHOS to the hormone treatment groups.
The ~80% recovery of blood perfusion throughout the ischemic 
duct contributed to the maintenance of GMT viability for 28 days 
after surgery (Fig. 3D) and ultimately led to full perfusion of the 
microchannel network throughout the VHOS at day 28 after surgery 
(Fig. 3E). In our previous study (2), the channel network underwent 
perfusion connection with in-growing host vessels within 2 weeks 
after implantation of the channel hydrogel into the ischemic hindlimb 
of mouse. Hence, in alignment with the in vitro results (Fig. 2C), 
these results indicate that the perfusion connection effectively res-
cued the hypoxic condition of hindlimb ischemia model, thereby 
robustly maintaining in vivo cell viability of GMT spheroids over the 
course of 28-day implantation. Consequently, the VHOS implanta-
tion (OVX + VHOS) significantly aided the recovery of endocrine 
function and adjusted the circulating plasma levels of 17-estradiol, 
progesterone, FSH, and LH to those comparable to the Ovary-intact 
group during the 30-day implantation period (Fig. 3F). In contrast, 
the hormone treatment groups (OVX + E and OVX + E + P) over-
produced sex hormone(s), indicating potential side effects on endo-
metrium regeneration. The OVX group maintained significantly 
lower levels of 17-estradiol and progesterone with markedly higher 
levels of FSH and LH compared to the other test groups, thereby 
validating the experimental model. The hormone dose was deter-
mined to match with the plasma 17-estradiol level as shown in a 
previous study (23), in which the same (200 to 250 pg/ml) plasma 
level of 17-estradiol was maintained (Fig. 3F). This higher dose 
range was used because of more beneficial effects on rodent models 
as shown in other previous studies (24–26). Moreover, because oral 
intake was used in this study, a dose loss through metabolism was 
considered to use the higher dose range.
Endometrium regeneration
Defective ovarian functions cause insufficient hormone production 
and endometrial dysfunction, resulting in histological (e.g., thin endo-
metrium) and functional (e.g., infertility) disorders (27). Hence, uterus 
and endometrium morphology were quantitatively analyzed by hema-
toxylin and eosin (H&E) staining (Fig. 4A) and ultrasonography 
(Fig. 4B) at 7 weeks after implantation of VHOS (i.e., 8 weeks after 
ovariectomy and induction of hindlimb ischemia) to compare endo-
metrium thickness and uterus thickness/index among the test groups. 
The OVX + VHOS implantation group regenerated the endometrium 
to the levels of the Ovary-intact group and the hormone-treated 
groups (OVX + E and OVX + P) as opposed to the OVX group.
The comparison of the Ovary-intact group with immediate im-
plantation of the VHOS also underscored the need to implant the 
VHOS 2 weeks before the comparison between the groups because 
of the significantly thinner endometrium and uterus observed in the 
OVX + VHOS group (fig. S2). Both the endometrium and uterus 
thicknesses of the OVX group were significantly thinner than those 
of the other three test groups as shown by quantitative analysis of 
H&E images. In alignment with these results, the OVX + VHOS group 
without a 2-week preincubation period had a significantly thinner 
endometrium than the Ovary-intact group, but the uterus thickness 
was not significantly different between the two groups (fig. S3). 
The endometrium thickness of the Ovary-intact group with 2-week 
preincubation was significantly thicker than those of the other three 
test groups, whereas only the uterus thickness of OVX group was 
significantly thinner than those of the other three test groups.
Attenuation of the side effects exerted by synthetic 
hormone therapy
The most prevalent concern surrounding standard hormone therapy 
is its adverse side effects, such as endometrial hyperplasia toward 
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Fig. 4. Endometrium regeneration by VHOS. VHOS implantation regenerated the endometrium to the levels of the Ovary-intact group as opposed to the OVX group 
(n = 3 to 6 rats). (A) Top: The morphological images (scale bar, 1 cm) were further examined by (middle) H&E staining (scale bar, 200 m) with (bottom) quantitative anal-
ysis (Ovary-intact, n = 4; OVX + E, n = 3; OVX + E + P, n = 3; OVX + VHOS, n = 3; OVX, n = 3). (B) Top: Ultrasonography images of uterus (original, 100×) were also obtained 
with magnification and labeling (200×), and then (bottom) the endometrium area of each group was quantitatively analyzed. Endometrium thickness and uterus index 
were compared among the test groups (each test group, n = 3). Data are means ± SEM. *P < 0.05 versus Ovary-intact; †P < 0.05 versus OVX. (Photo credit: Hyo-Jin Yoon, 
Yonsei University College of Medicine.)
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cancer progression and deep vein thrombosis (28). Therefore, the pri-
mary advantage of VHOS implantation was revealed upon show-
ing the hyperplasia features of hormone treatment groups in 
the H&E staining with quantitative image analysis (Fig. 5A). The 
hormone treatment groups (OVX + E and OVX + E + P) signifi-
cantly increased the hyperplasia area and number compared to the 
OVX group, whereas the OVX + VHOS group maintained normal 
levels comparable to that of the OVX-intact group. Because endo-
metrial hyperplasia is considered a potential inducer of uterine cancer 
(29, 30), expression of cancer markers (p53 and PTEN) was exam-
ined by immunohistochemistry (IHC) and Western blot (Fig. 5B). 
Both markers are representative tumor suppressors; however, p53 
expression increases (31), whereas PTEN expression decreases (32) 
upon the development of endometrial cancer. The hormone treat-
ment groups exhibited significant increases in p53 expression with 
significant reductions of PTEN expression compared to the Ovary- 
intact and OVX groups. However, these expression patterns were 
opposite to what was observed in the OVX + VHOS group, indicat-
ing a promising potential to attenuate the side effects of hormone 
therapy by using VHOS implantation.
The standard hormone replacement therapy is also known to 
significantly promote deep vein thrombosis and pulmonary embo-
lism, which justifies the need to assess this outcome given that it is a 
side effect of hormone injection (33, 34). When transmission elec-
tron microscopy (TEM) analysis was applied after ligating the infe-
rior vena cava, the two hormone administration groups exhibited 
significantly more instances of deep vein thrombosis than the other 
groups (Ovary-intact, OVX, and OVX + VHOS group) (Fig. 5C). In 
particular, this side effect was absent in the OVX + VHOS group 
similar to the Ovary-intact group, which further confirmed the 
potential of the VHOS to be an effective alternative to standard 
hormone therapy.
Prevention of menopause-related health risks
Because menopausal women are at risk of gaining fatty weight and 
experiencing osteoporosis (35), these side effects were also assessed 
(Fig. 6). Although slight decreases were observed in all groups during 
the first week, each test group showed an overall incremental trend 
in average body weight for 8 weeks (Fig. 6A). Compared to the OVX 
group, the OVX + VHOS group significantly decreased body weight 
and fat percentage comparable to that of the Ovary-intact group, 
indicating the therapeutic potential of the VHOS to attenuate the 
health risk related to menopause. However, both hormone treat-
ment groups (OVX + E and OVX + E + P) showed heavier body 
weights and a lower fat percentage compared to the Ovary-intact 
group, reproducing the undesirable side effects exerted by synthetic 
hormone treatment.
Next, dual-energy x-ray absorptiometry (DEXA) and micro–
computed tomography (micro-CT) were applied to compare pro- 
osteoporosis effects among the test groups (fig. S4). The OVX + VHOS 
group rescued the loss of bone mineral density (BMD) and bone 
mineral content (BMC) phenotypes seen in the OVX group and 
thereby maintained BMD and BMC comparable to that of the Ovary- 
intact group (Fig. 6B). In contrast, both hormone treatment groups 
showed side effects of increasing BMC and/or BMD significantly 
above the normal levels (Ovary-intact). The bone loss rescue effect 
of the OVX + VHOS group compared with the bone loss of the 
OVX group is supported by the quantitative analysis of micro-CT 
images (Fig. 6C). In this case, only the OVX group showed significant 
bone loss compared to the other four test groups, which validates the 
reliability of the animal model. These results highlight the potential 
of VHOS implantation to reduce the health risks related to meno-
pause such as an increase in body/fat weight and osteoporosis.
DISCUSSION
The artificial ovary in the form of a multilayered GMT spheroid was 
designed to recapitulate the major function of the ovary to produce 
sex steroid hormones to attenuate health risks related to menopause 
without side effects. The present results could not have been achieved 
if the vascular network hydrogel did not support the actions of arti-
ficial ovaries in vitro and in vivo. In particular, the 3D perfusion- 
based continuous supply of oxygen and nutrients, provided by the 
artificial ovary, enabled the robust maintenance of GMT viability 
and function. In our previous animal study (36), a rabbit underwent 
partial hepatectomy; the liver tissue was minced; the tissue pieces 
were directly loaded into the channel hydrogel without any cell cul-
ture; and, finally, the tissue-loaded hydrogel was implanted into the 
hepatectomy site in the rabbit. These procedures of the previous 
study highlight the novelty of the present study that includes cultur-
ing ovary spheroids onsite of implantation where perfusion connec-
tion between the channel network and host vessels was induced by 
the hypoxia condition of hindlimb ischemia model. The VHOS im-
plantation into the ischemic hindlimb resulted in the efficient pro-
duction and subsequent release of autocrine hormones from the 
GMT in a sustained fashion via perfusion supplied by the growth of 
the host vessel into the channel network.
Moreover, the total number of cells in spheroids was matched 
with that of the rat ovary (4.7 × 106 of each cell type) (37). Following 
the layer-by-layer construction as a major trend of modern tissue 
engineering approach (38), the structure of GMT spheroid was 
designed. In particular, the critical need of Matrigel (M) coating as 
basal lamina mimetic was shown in our study given the follicle matu-
ration and function of GMT spheroids compared with GT spheroids. 
The concept that ECM regulates cell behavior and tissue develop-
ment has been applied to study ovary functions (39). When ovarian 
follicles receive an action signal, precursor G cells undergo matura-
tion by a phenotype switch from a squamous to cuboidal shape, and 
oocyte growth is supported by forming a single layer of these G cells 
to surround follicles. To strengthen this support, expansion of basal 
lamina plays a critical role in forming multilayers from this single 
layer upon proliferation of G cells, leading to two-layer and then 
multilayer stages of follicles. Also, the basal lamina is critically re-
quired to recruit T cells, which thereby form the outer layer of the 
ovarian follicle. This principle has been confirmed by a recent study 
reporting single or synergistic effects of collagen (types I and IV), 
fibronectin, laminin, Matrigel, and other ECM proteins on morphol-
ogy, survival, proliferation, and steroidogenesis of G cells, follicles, 
and ovaries (40). The results of the present study (Fig. 2C) are also 
aligned with this principle, as inclusion of basal lamina promoted the 
stability, survival, and proliferation of ovary spheroids through per-
fusion culture in the VHOS. The effective hormone production of 
GMT spheroids validates a causative role of Matrigel coating in facil-
itating cooperation of G and T cell layers, representing another aspect 
of technical advance in the field. The combination of these factors 
demonstrated the potential not only to overcome the long-standing 
issues associated with standard hormone therapy but also to regen-
erate endometrium histologically and functionally in vivo.
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Fig. 5. VHOS-mediated attenuation of side effects from hormone therapy. The advantage of VHOS implantation was shown by presenting the side effects (i.e., hyper-
plasia, cancerous progress, and deep vein thrombosis) of the hormone treatment groups (Ovary-intact, n = 4; OVX + E, n = 5; OVX + E + P, n = 6; OVX + VHOS, n = 5; OVX, 
n = 5), as supported by the following data. (A) H&E staining (scale bar, 100 m) with quantitative analysis of hyperplasia area (left) and number (right). White arrows indi-
cate endometrial hyperplasia, a potential inducer of uterine cancer. (B) Expression of p53 and PTEN as indications of endometrial carcinoma progress and suppression, 
respectively, by (top) IHC images (scale bar, 100 m) with (middle) quantitative analysis (each test group, n = 4) and (bottom) Western blot with quantitative analysis. Data 
are means ± SEM. *P < 0.05 versus Ovary-intact; †P < 0.05 versus OVX. (C) TEM analysis of deep vein thrombosis after ligation of inferior vena cava (scale bar, 5000 nm).
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Fig. 6. Prevention of menopause-related health risks using VHOS implantation. (A) Gaining body weight and fat percentage, as indications of menopause risk, for 
8 weeks (Ovary-intact, n = 4; OVX + E, n = 5; OVX + E + P, n = 6; OVX + VHOS, n = 3; OVX, n = 5). (B) Losses of BMD and BMC as other side effects of menopause, analyzed by 
quantitative analysis of DEXA scans (Ovary-intact, n = 4; OVX + E, n = 5; OVX + E + P, n = 6; OVX + VHOS, n = 3; OVX, n = 5). (C) Qualitative scan images (top) of the femoral 
micro-architecture by micro-CT with quantitative image analyses of four bone density indexes (BV/TV, bone volume/total volume; Tb.Th, trabecular thickness; 
Tb.N, trabecular number; Tb.Sp, trabecular separation) from a 3D reconstruction area of rat femoral bone, comparing the density (red arrow) and cavity (white arrow) in 
trabecular bone fracture with those of OVX group (Ovary-intact, n = 4; OVX + E, n = 5; OVX + E + P, n = 6; OVX + VHOS, n = 5; OVX, n = 5). Data are means ± SEM. *P < 0.05 
versus Ovary-intact; †P < 0.05 versus OVX.
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According to general clinical guideline, the plasma hormone level 
is presented as picograms per milliliter or nanograms per milliliter, 
and the variation of subjective weight such as human versus mouse 
is normalized to blood volume/weight kilogram. Because this unit is 
similar between human (65 ml/kg) and mouse (64 ml/kg) as reported 
previously (41), the normal level of plasma hormone is not much 
different between the two species. A previous study has reported 
that normal women in a fertile period have an average of 19.5 to 
356.7 pg/ml of estradiol and 0.11 to 5 ng/ml of progesterone, while 
female rats have 50 to 70 pg/ml of estradiol and 7 to 10 ng/ml of 
progesterone (23). In our in vivo study (Fig. 3F), the OVX + VHOS 
group secreted an average of 50 pg/ml of estradiol and 5 ng/ml of 
progesterone, and thus, the hormone levels are aligned with the 
hormone level ranges of normal women and female rats. These results 
confirm a promising potential of the implantable ovary to rescue 
ovary dysfunctions not only for rats but also in a clinical setting.
Cryopreservation and implantation of autologous oocyte and 
embryo have served as the standard approach to restore impaired 
ovary functions that result from menopause and systemic cancer 
(e.g., leukemia). However, the intrinsic risk of this method to rein-
troduce autologous cancer cells during the implantation remains a 
critical limitation (42). Hence, the significance of our approach lies in 
the fact that ovarian functions (43) were repaired through isolation 
and grafting of pre-antral follicles using transplantable artificial 
ovaries. Notably, the major trend of current research is to restore, 
repair, and regenerate the whole ovarian setting, including follicle 
development, ovulation, hormone production, and healthy embryo-
genesis, as shown in multiple murine models (14, 44–47). Despite 
continuous progress of this trend, specification of single purposes 
(e.g., hormone release) in fine-tuning the approaches appears to be 
more effective than regenerating the whole ovarian setting consider-
ing ovary physiology. For example, hormone production does not 
require an oocyte and can be operated by the function of G and T cells 
(23, 48). Our approach is aligned with this tunable design concept, 
as shown in the layer-by-layer formation of GMT with the user- 
specified application of a 3D channel network hydrogel.
The present results indicate that a transplantable VHOS may be 
a promising method as a cell-based menopausal hormone therapy. 
The effective hormone production by the VHOS played a pivotal role 
in target organs and significantly reduced the health-related risks 
related to menopause without side effects seen with standard hor-
mone therapy. Female hormone production is regulated through a 
feedback mechanism of the hypothalamic-pituitary-ovarian (HPO) 
axis. The release of GnRH from the hypothalamus can be indicated 
by the FSH and LH levels because of the direct links of their produc-
tion through the feedback mechanism of the HPO axis. Cessation of 
estrogen production because of menopause increases the levels of 
FSH and LH by the axis action. In contrary, the rescue of menopause 
such as a VHOS implantation induces releases of estrogen and pro-
gesterone and thereby decreases the secretion levels of FSH and LH 
through the negative feedback mechanism. This rationale justifies 
the measurement of FSH and LH levels as an indication of the feed-
back mechanism of the HPO axis. In this study, the GnRH concen-
tration was not directly measured because GnRH is secreted in a 
pulsatile fashion with various frequencies and amplitudes (49). Thus, 
the measurement at a certain moment appeared to not be meaningful. 
Our results indicate effective synchronization of the VHOS with the 
HPO axis as seen in innate physiology. Also, compared to the over- 
thickness, hyperplasia, and cancerous progress of endometrium as 
well as deep vein thrombosis shown in the synthetic hormone treat-
ment groups, the proper structural regeneration with an intricate 
cross-talk of reproductive hormone secretion through the VHOS 
implantation is meaningful in terms of a safe menopausal hormone 
therapy. Together, the advantages of our approach represent a break-
through concept to rescue the loss of ovarian function seen in a large 
population of women with menopause, or those who have had ex-
posure to gonadotoxic agents.
Despite the promising results, clinical uses of autologous cells and 
hindlimb ischemia model should be carefully examined through 
further studies. Intrinsic risks remain in reintroducing autologous 
cancer cells during the implantation (42). However, as shown by pre-
vious clinical studies (50–52), it is possible to harvest ovarian tissues 
from ovarian cancer patients or huge ovarian cyst-positive patients. 
Because removing less than 30% of an ovary has minimal detrimental 
effect (53), studies have been conducted by clinicians to preserve 
ovarian functions of premenopause women undergoing chemo-
therapies or radiation therapies and to preserve fertility functions of 
women with premature ovarian failure. Despite the need to thoroughly 
investigate for cancer contamination, the aforementioned evidences 
indicate a promising possibility of harvesting ovary tissue and im-
planting autologous ovary cells with the VHOS to the same donor 
patient for clinical purposes.
However, there is a definite need to reconsider the hindlimb 
model for clinical translation. Our previous study has reported that 
it is also possible to vascularize the channel hydrogel by implanting 
in other sites such as greater omentum and subcutaneous areas, 
because these sites can be subjected to perfusion connection be-
tween host vasculature and the implanted hydrogel (2). Also, tissue- 
engineered ovarian constructs were successfully transplanted into 
ovarian bursa (45), kidney capsule (54), and omental pouch (23, 55), 
although these sites were nonhypoxic conditions. Nonetheless, be-
cause implantation to these sites requires invasive surgical processes, 
reimplanting the hydrogel into the donor site where the ovaries 
were harvested is also considered. These candidate models will be 
thoroughly tested in further studies to exert most efficient clinical 
outcomes. As another follow-up study, rat follicles will be harvested 
to examine oocyte maturation through optimization of the VHOS 
design. In addition, a preclinical model of cancer-mediated fertility 
loss will be developed to determine whether the current approach 
can be used as a therapeutic for this critical situation. Because it 
took 2 weeks to produce hormones in our model, the VHOS design 
and implantation site will be further improved to accelerate this pro-
cess. These current and future efforts will be merged to move toward 
translation to clinic so that a previously unidentified biotechnical 
platform can be introduced to the underexplored but indispensable 
area with a huge clinical potential.
METHODS
Reagents and antibodies
Medium 199, McCoy’s 5A medium, and fetal bovine serum (FBS) 
were purchased from Gibco BRL (Grand Island, NY, USA). Percoll, 
insulin-transferrin-selenium mix, and deoxyribonuclease (DNase) 
I were obtained from Sigma-Aldrich (St. Louis, MO). Collagenase 
type 1 was purchased from Worthington (Lakewood, NJ), and insulin- 
like growth factor–I (IGF-I) was provided by PeproTech (Rocky Hill, 
NJ). Estradiol valerate was obtained from Bayer (Progynova; Bayer, 
Leverkusen, Germany), and progesterone was purchased from Pfizer 
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(Provera; Pfizer Inc., NY, USA). Primary antibodies for PCNA and 
cyclin D1 were purchased from Cell Signaling Technology (Danvers, 
MA, USA). Antibodies against FSH-R, LH-R, CYP17A1, and CYP19 
were obtained from Abcam (Cambridge, UK). -Actin was obtained 
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Sex steroid 
(estrogen and progesterone) enzyme-linked immunosorbent assay 
(ELISA) kits were provided by Enzo, Life Sciences (Plymouth Meeting, 
PA, USA). The FSH and LH ELISA kits were purchased from Tsz 
Biosciences (San Francisco, CA, USA). The vendors for other chemicals 
and reagents are denoted in the corresponding sections of Methods.
Cell harvest from rat ovaries
Endocrine cells were harvested from immature rat ovaries follow-
ing the protocol described in a previous study (23). Briefly, ovaries 
were collected in ice-cold medium 199 (M199) with supplements of 
Hepes (25 mM), bovine serum albumin (BSA; 1 mg/ml), l-glutamine 
(2 mM), penicillin (10,000 IU/ml), streptomycin (10,000 g/ml), and 
amphotericin B (25 g/ml) after removal of extraneous tissue, fol-
lowed by washing three times with M199 medium. Then, the ovaries 
were punctured using 30-gauge needles to remove loosely packed 
granulosa from the follicles. Leftover ovary tissues were collected 
and incubated with collagenase (2 mg/ml) and DNase (10 g/ml) in 
M199 for 90 min by mixing occasionally. Next, tissue pieces from 
the enzyme digestion underwent dispersion and discontinuous Percoll 
gradient separation, followed by fractional collection of G and T cells 
as described previously. The purities of G and T cells were deter-
mined by flow cytometry analysis of G cell–specific CYP19 and 
T cell–specific CYP17A1 markers.
Microchannel network hydrogel with ovarian 
spheroids (VHOS)
To produce GT or GMT (M: Matrigel as basal lamina mimetic) 
spheroids, G cells (1.4 × 106 cells/ml) were first seeded in AggreWell 
and centrifuged together, to produce G spheroids in culture over 
24 hours. The G spheroids were then collected and cultured in M 
with growth medium, resulting in M coating onto the spheroid sur-
face, followed by culture for more than 24 hours. Next, T cells 
(0.7 × 106 cells/ml) were sprayed on the GM spheroid surface in an 
AggreWell to produce a multilayered follicle in the form of a GMT 
spheroid with a 2:1 ratio of G (1.4 × 106):T (0.7 × 106) in each spheroid, 
with the structural and compositional similarities to those of native 
follicles (Fig. 1). The M coating step was omitted during the pro-
duction of GT spheroids.
A VHOS was produced by culturing cell spheroids in a micro-
channel network hydrogel using PNIPAM (Mn ~ 40,000, Sigma- 
Aldrich, St. Louis, MO) as a sacrificial material and gelatin as a 
hydrogel material following our recent reports (2, 22) (Fig. 2A). The 
PNIPAM fiber diameter was controlled by adjusting the rpm (2500 to 
2800 rpm) of a custom-built spinning device (18) after dissolving in 
a MeOH solution (45%, w/v). The fibers were placed into a PDMS 
mold at a density of 11.45 ± 3.13 g mm−3, and then a silicone tube 
was placed to connect with the fibers at the inlet and outlet sides. In 
this way, medium or blood could be perfused through the inlet sili-
cone tube of the fiber-generated channel network and finally to the 
outlet silicone tube. Next, a gelatin/mTG solution (5%, w/v) with 
cell spheroids was poured onto the fibers, followed by crosslinking 
at 37°C. The embedded fibers were dissolved from the mTG hydrogel 
by sol-gel transition of PNIPAM at room temperature by perfusing 
phosphate-buffered saline (PBS). Static or dynamic culture was 
conducted with or without perfusing medium at a continuous flow 
rate of 20 l/min through the channel network, respectively, for 
30 days to mimic a 30-day menstrual cycle. The total number of cells 
(2.1 × 106) in each spheroid was matched with that of the rat ovary 
(2:1 = 1.4 × 106 G:0.7 × 106 T) (37). As shown previously (36), the 
perfusibility of the channel networks in the gel body was determined 
by perfusing microfluorescent beads (2 m for flow tracking) in cul-
ture medium (20 l/min). The spatial velocity of each microbead in 
the microcapillary networks of gelatin hydrogel was analyzed with a 
particle tracker plugin (the MOSAIC group) in ImageJ/Fiji soft-
ware and visualized to the color map using MATLAB software 
(MathWorks, USA).
Rat ovariectomy and hindlimb ischemia
All animal experiments were approved by the Institutional Animal 
Care and Use Committee (IACUC) of Yonsei University College of 
Medicine (authorization number 2019-0070). Immature female rats 
(3-week-old Fisher 344) were purchased from Central Lab Animal 
Inc. (Seoul, South Korea) and maintained under a specific pathogen–
free condition with a 12-hour interval light-dark cycle. Hindlimb 
ischemia was generated as described in a previous report (2) by li-
gating the upper and lower points of the femoral artery in left limbs 
using a 4-0 silk suture (Ethicon, Somerville, NJ), followed by sepa-
ration and dissection of the femoral artery from the femoral vein. 
The VHOS was then implanted into the hindlimb muscle. Next, 
progressive increases in blood flow were monitored at days 0, 7, 14, 
and 21 after surgery by laser Doppler perfusion imaging (LDPI; 
Moor Instruments, Devon, UK) with quantitative analysis of LDPI 
values. The highest and lowest values of perfusion (LDPI) were color- 
coded to red and dark blue, respectively. The relative blood flow 
ratio was determined by calculating the perfusion percentage of the 
left ischemic hindlimb to that of the right normal hindlimb.
Fisher 344 female rats were subjected to surgical bilateral ovari-
ectomy to remove the ovaries (OVX) and grouped according to the 
designated test conditions (n = 3 to 6). After the rats were allowed 
to reach a stable level of baseline plasma hormones (Fig. 3A), the rats 
underwent either VHOS implantation (OVX + VHOS) or hormone 
treatment with estradiol only (OVX + E) (1 mg/kg, n = 5) or E + 
progesterone (OVX + E + P) (1 and 2.5 mg/kg, respectively, n = 6) 
through oral injection every 4 to 5 days to mimic the menstrual 
cycle of rats. The sham-operated group served as a normal model 
(Ovary-intact, n = 3), and the OVX group served as a surgical con-
trol (n = 5). Body weight and plasma hormone levels (17-estradiol, 
progesterone, FSH, and LH), assessed using blood draws, were checked 
every week for 42 days.
Protein expression and production
Cells were plated on eight-well chamber slides (0.5 × 104 cells per well) 
and fixed with 95% methanol for 10 min at −20°C for immunofluo-
rescence staining. After rinsing with PBS containing 0.1% Tween 20 
(PBST), cells were incubated with 0.2% Triton X-100 in PBS for 
5 min, washed three times with PBST, and blocked for 2 hours with 
PBST (pH 7.4) containing 5% BSA. Samples were treated with CYP19 
or CYP17A1 primary antibodies (1:100) in PBST with 1% BSA over-
night at 4°C and washed three times with PBST. Then, samples were 
treated with tetramethylrhodamine isothiocyanate–conjugated anti- 
mouse or fluorescein isothiocyanate (FITC)–conjugated anti-rabbit 
immunoglobulin G secondary antibodies (1:1000) in PBST with 1% 
BSA at room temperature for 1 hour. Cell nuclei were counterstained 
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with 4′,6-diamidino-2-phenylindole (DAPI) and rinsed with PBST. 
Confocal imaging (Leica Microsystems, Heidelberg, Germany) was 
applied to analyze the fluorescence signals with quantitative analysis 
using ImageJ software (National Institutes of Health, MD, USA).
For flow cytometry, cells were washed with PBS containing 2% FBS 
and 0.1% Tween 20 and then stained with CYP17A1-phycoerythrin 
(PE) and CYP19-FITC for 30 min at 4°C. Next, cells were collected, 
washed with PBS again, and dissociated into single cells using a 
strainer (40-m-diameter pores). BD FACSCalibur (Becton Dickinson 
Biosciences, San Jose, USA) was used to determine the population 
of CYP19+ G cells and CYP17A1+ T cells.
For Western blot analysis, cells were lysed by scrapping in radio-
immunoprecipitation assay buffer for 30 min on ice, centrifuged at 
13,000g for 15 min to collect protein supernatants, and stored at −70°C. 
The protein concentration was determined using a BCA protein as-
say kit (Pierce, Rockford, IL, USA), followed by separation by a 10% 
(w/v) SDS–polyacrylamide gel electrophoresis and electrotransfer-
ring onto a nitrocellulose membrane. The membrane was blocked 
with 5% nonfat dry milk in tris-buffered saline buffer containing 
0.1% Tween 20 (TBST) for 1 hour at room temperature. Samples 
were then incubated with primary antibodies (PCNA, cyclin D1, 
FSH-R, and LH-R) in TBST overnight at 4°C and rinsed with TBST 
three times. Blots were treated with horseradish peroxidase–conjugated 
secondary antibodies (rabbit, mouse, or goat) in TBST for 1 hour at 
room temperature and washed again three times with TBST. The 
protein bands were visualized using an enhanced chemiluminescent 
(ECL) detection kit (Amersham Pharmacia Biotech, Buckinghamshire, 
UK), and quantitative analysis of the band intensities was done us-
ing LAS-3000 Image Analyzer (Fujifilm, Tokyo, Japan).
Cell viability, spheroid circularity, and channel perfusion 
staining in VH
Cell viability of spheroids in VH was assessed using a live/dead assay 
either after 30-day in vitro perfusion culture or 28-day implantation 
into an ischemic hindlimb of mouse. Cells in the VH were incubated 
in medium containing calcein AM and ethidium homodimer-1 
(Thermo Fisher Scientific, Waltham, MA, USA) for 15 min and 
subjected to LSM 780 confocal imaging. When the stability of spher-
oid was disturbed, their structure changes from a nearly complete 
circle to an irregular structure, thereby decreasing the circularity 
(complete circle: 1 → 0) (20). Therefore, the circularity of the spher-
oids was determined after 30-day in vitro culture of the test groups 
using the confocal images of spheroids after live/dead staining with 
the quantitative image analysis using ImageJ (version 1.52a). Flow 
perfusion connection from neighboring vessels to channel networks 
in implanted hydrogels was determined following the protocols used 
in previous studies (21, 56). Each rat’s inferior vena cava was cut 
out to make a blood drain point, and then heparin sulfate in PBS 
(0.1 mg ml−1) was injected into the left ventricle to remove whole 
blood. Next, red fluorescence microbeads (45 nm in diameter, 
Invitrogen, Grand Island, NY) in heparinized PBS were perfused 
through the left ventricle to visualize perfusable vessels connected 
to channels by LSM 780 confocal laser scanning microscopy.
Functional and histological recovery after ovariectomy
The hormone levels, in culture medium or blood plasma after orbital 
sinus blood sampling, were determined to test the endocrine func-
tions of the cell spheroids over time. The levels of sex steroid 
hormones (17-estradiol and progesterone), FSH, and LH were 
measured using ELISA kits (17-estradiol and progesterone from 
Enzo Life Sciences, Plymouth Meeting, PA; FSH and LH from TSZ 
ELISA, Framingham, MA) according to the manufacturer’s instruc-
tions. This was followed by quantitative reading of the color inten-
sities using a colorimetric microplate reader (BioTek).
For histology, rat uterine tissues were harvested, fixed in 4% para-
formaldehyde for 24 hours, embedded in paraffin blocks, sectioned 
to a 4-m thickness, and stained with H&E. Microscopy imaging of 
the longitudinal uterine sections was used to determine histological 
recovery by calculating thicknesses (i.e., radius from the central 
end to the outer end in each sample) of myometrium and endome-
trium (n = 4 to 6).
Side effects of synthetic hormone therapy
The degree of venous thrombosis after ligation of the inferior vena cava, 
as an indication of side effects from hormone therapy, was determined 
by TEM. Each group specimen was fixed in 2% glutaraldehyde–2% 
paraformaldehyde in 0.1 M phosphate buffer (pH 7.4) for 12 hours, 
with subsequent rinsing in 0.1 M phosphate buffer. The specimens 
were then incubated with 1% OsO4 in 0.1 M phosphate buffer for 
2 hours and dehydrated with a series of ethanol solutions at incre-
mental concentrations (50, 60, 70, 80, 90, 95, 100, 100%) for 10 min 
each, followed by treatment with propylene oxide for 10 min. Next, 
the specimens were subjected to polymerization using a Poly/Bed 
812 kit (Polysciences) in an electron microscope oven (TD-700, 
DOSAKA, Japan) at 65°C for 12 hours. The specimen blocks were 
cut into 200-nm semi-thin sections and stained with toluidine blue 
for optical microscope imaging, followed by further cutting of the 
areas of interest into 80-nm-thin sections. The sections were placed 
onto copper grids, double-stained with 3% uranyl acetate for 30 min 
and 3% lead citrate for 7 min, and imaged by TEM (JEM-1011, JEOL, 
Tokyo, Japan) at the acceleration voltage of 80 kV with a Megaview 
III charge-coupled device camera (Soft Imaging System, Germany).
Expression of cancer markers (p53 and PTEN) was determined 
by IHC after cutting the uterus tissue of each group into 4-m sec-
tions, fixing the tissue in 10% formalin, and embedding it in paraffin. 
Samples were deparaffinized three times with xylene, rehydrated with 
alcohol, heated using a microwave, and boiled twice for 6 min in 
10 mM citrate buffer (pH 6.0) for antigen retrieval. Each section was 
blocked by treating with 3% hydrogen peroxide and 4% peptone 
casein solution for 15 min. Next, the sections were incubated with 
p53 and PTEN antibodies (Abcam, Cambridge, UK) at room tem-
perature for 40 min in TBS containing 0.05% Tween 20. The sections 
were incubated with horseradish peroxidase–conjugated secondary 
antibodies (rabbit or mouse; Dako, Glostrup, Denmark), followed 
by optical imaging. For quantitative image analysis, the tissue area 
in each acquired image was defined, and the expression-positive color 
intensity of the tissue area was measured using ImageJ, followed by 
normalizing the intensity to the tissue area. Then, the average value 
of each group was divided by that of OVX-intact group (=1) to de-
termine the degree of relative expression in each test group.
Menopause-related health risks
DEXA (InAlyzer, MEDIKORS Inc., Gyeonggi, Korea) was used to 
determine fat accumulation in the whole body of each rat. Rat femur 
bones were collected and analyzed by cone-beam x-ray micro-CT 
(Nano Focus Ray Co. Ltd. Polaris-G90, Korea), and quantitative 
analysis of the following parameters was done using a 3D-rendering 
software (RadiAnt DICOM Viewer 4.2.1): BMD, BMC, fractional 
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trabecular bone volume [BV/TV (%)], trabecular thickness [Tb.Th (m)], 
trabecular number [Tb.N (1/mm)], and trabecular separation 
[Tb.Sp (m)].
Statistical analysis
Statistical differences between the experimental groups were ana-
lyzed using Excel and SigmaPlot V.8.0 (SPSS Inc.). Data were rep-
resented as means ± SEM of a minimum of three independent 
experiments. Statistical significance was determined by a two-tailed 
Student’s t test or one-way analysis of variance (ANOVA) with 
Tukey’s significant difference post hoc test for multiple comparisons. 
Values of *P < 0.05, **P < 0.01, and ***P < 0.001 were considered 
statistically significant. The sample size of biologically independent 
samples per group and/or the number of independent experiments 
are indicated in the figure legends where applicable.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/7/18/eabe8873/DC1
View/request a protocol for this paper from Bio-protocol.
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